Luma’s technology is based on Photonic Integrated Circuits (PICs) — the light-based equivalent of electronic integrated circuits. Silicon PICs are proven to have significant biosensing and diagnostic capabilities. This has been demonstrated by commercial companies and thousands of published scientific papers. However, commercialization of these solutions for home use has been limited due to the high associated costs.
Luma has pioneered and developed the world’s first, fully operational polymeric PICs, which exhibit optical properties comparable to their Silicon counterparts. The significant cost reduction of polymeric PICs, while maintaining comparable optical properties, paves the way towards a sensitive, rapid, multi-omics, low-cost solution for the home testing market.
Exciting opportunities
for Luma’s platform ——————————————
Autoimmune Diseases
—
- Autoimmune diseases affect about one in ten individuals (!) - $15B by 2033.
- Unpredictable disease flares cause significant clinical & financial burden.
- The Luma solution would diagnose exacerbations early, allowing patient- tailored preventive strategies (e.g.,Lupus, IBD, MS).
Clinical Drug Development
—
- Clinical trials is a huge market undergoing decentralization.
- More than 6000 ongoing clinical trials involving Immunology alone.
- The Luma solution can be leveraged for improved drug development of immune-related drugs.
Sexually Transmitted Diseases
—
- More than 20 million estimated new cases in the United States each year.
- Expensive ($150) mail-in tests are the only choice for home testing with waiting time of several days for results.
- The Luma solution could capture a significant share of this huge market (99B USD in 2027).
We are Luma
Luma Biophotonics has a multidisciplinary team of experts in physics, engineering, biotechnology, pharmaceuticals, business, and more
Ofer Bar-On
Co-founder and CEO
—
10 years of experience in polymer based photonic integrated circuits, both in theory and manufacturing. Ph.D. in optics and nanotechnology (Tel-Aviv University)
Omer Kotlicki
Co-founder and CTO
—
More than 20 years of experience in optics, electronics and IT, both industry and academy. Ph.D. in electrical engineering (Tel-Aviv University)
Giora Volpert
VP R&D
—
Bio convergence expert; Ph.D in Biochemistry (The Weizmann Institute of Science); Years of experience in commercial development of biosensors and multidisciplinary medical devices (Vensice Medical, Ador Diagnostics).
Dorit Sokolov
Business and Strategy
—
Multi-disciplinary early-stage Biotech & HealthTech investor and company builder with significant passion for innovation, venture creation, business development and bringing novel medical products to market.
Daniel Woolman
Supply Chain Management
—
Experienced co-founder of two engineering and manufacturing companies.
Lina Kanyavskaya, Research Assistant in Biochemistry
—
M.Sc in Biotechnology. Experienced researcher in the fields of molecular biology and biochemistry.
Michael Chasnitsky
Head of Integrated Photonics
—
Ph.D. From the Hebrew University. An experienced physicist with background in nanotechnology, wave propagation, and plasmonics.
Scientific Advisory Board
Michal Stein
—
M.D. (Hebrew University), Head of Pediatric Infectious Disease Unit, Sheba Hospital and chair of the Israeli Society of Pediatric Infectious Diseases.
Aviram Hochstadt
—
M.D. (Hebrew University), M.P.H (Tel-Aviv University) Senior physician in cardiology and internal medicine, EP Fellow at NYU Langone Health.
Prof. Jacob Scheuer
—
Senior professor at the department of electrical engineering at Tel Aviv University and Author of more than 150 scientific papers and 10 patents in the field of optics.
Ari Tadmor
—
Former CEO of ADOR Diagnostics, a molecular diagnostics company. PhD in biology (The Weizmann Institute of Science). An experienced executive in the diagnostics field.